Altered Expression of FAS System Is Related to Adverse Clinical Outcome in Stage I-II Breast Cancer Patients Treated with Adjuvant Anthracycline-Based Chemotherapy

Claudio Botti(Catholic University of America), Marcella Mottolese, Franca Del Nonno(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Franco Di Filippo, Pier Giorgio Natali(Unknown), Maria Benevolo(Istituti di Ricovero e Cura a Carattere Scientifico), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), F. Cognetti(Sapienza University of Rome), Simonetta Buglioni, Franco Maria Venanzi(Università di Camerino), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico)

Clinical Cancer Research

February 15, 2004

10.1158/1078-0432.ccr-1092-03

Cited by 40

Related Papers

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

|Annals of Oncology|2016|398

Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.

|Journal of Clinical Oncology|1998|246

Extracellular Matrix Molecular Remodeling in Human Liver Fibrosis Evolution

|PLoS ONE|2016|245

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

|Clinical Cancer Research|2019|240

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

|Journal of Clinical Oncology|2022|231